The Lancet Oncology Publishes Results From SYMPLIFY Study Of A Multi-cancer Early Detection Test In Symptomatic Patients Using Grail's, An Illumina Company, Test Showing An Overall Cancer Signal Origin Prediction Accuracy Of 85.2%
Portfolio Pulse from Benzinga Newsdesk
The Lancet Oncology published results from the SYMPLIFY study of Grail's multi-cancer early detection test in symptomatic patients, showing an overall cancer signal origin prediction accuracy of 85.2%. Grail is an Illumina company.
June 21, 2023 | 7:59 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Illumina's Grail achieves 85.2% accuracy in multi-cancer early detection test, according to The Lancet Oncology's SYMPLIFY study publication.
The publication of the SYMPLIFY study results in The Lancet Oncology, a reputable medical journal, validates the effectiveness of Grail's multi-cancer early detection test. This positive news is likely to boost investor confidence in Illumina (ILMN), the parent company of Grail, and may lead to an increase in stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100